Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Swedish Orphan Biovitrum Ab (OP: BIOVF )

23.21 +0.10 (+0.44%)
Streaming Delayed Price Updated: 1:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 23.21
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 23.11
Today's Range 23.21 - 23.21
52wk Range 18.40 - 24.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
 
Via Benzinga
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Veru Inc. 
Via Benzinga

Performance

YTD
+9.75%
+9.75%
1 Month
+2.08%
+2.08%
3 Month
+9.75%
+9.75%
6 Month
+19.70%
+19.70%
1 Year
-3.28%
-3.28%

More News

Read More
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Via Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Via Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Via Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Via Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.